Prediction Case File
YouTubeEvaluation Complete

Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]

1 extracted signal · 1 resolved · 0 still active

StockInvest.us profile imageStockInvest.usIndependent analyst profile
Source published
04 Nov 2025, 04:48 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Nuvation Bio Inc. Stock Prediction and Forecast [NUVB]
Source overview

AI-generated source summary

The analysis indicates Nuvation Bio Inc. as a Buy Candidate with a score of 3.304 as of November 3rd, 2025. It has demonstrated a gain of 39.73% over the past 11 days, averaging 3.61% daily. The stock is positioned within a robust short-term upward trend, with a potential change of approximately 74.83% over the next three months, and a 12-month forecast projecting a 24.39% change, with a price range between $2.63 and $6.70. On November 3rd, 2025, the stock closed at $5.17, experiencing a 0.96% decrease with a daily fluctuation of 5.49% and a volume of 7 million shares. Its 52-week high was $5.55, while the all-time high was $15.23 on May 26th, 2021. News includes 204 new patients receiving IBTROZI, regulatory approval in Japan, and insider trading activity showing both purchases and sales. However, general ratings indicate a Strong Sell for Return on Equity, Return on Asset, and Dividend Earnings, with a negative P/E ratio of -8.68. Technical signals show short and long-term Moving Averages giving a positive forecast, with a MACD buy signal and a Bollinger Band buy signal from 57 days ago. There is a sell signal from a pivot top found 4 days prior, indicating a 3.72% decline since. The stock exhibits very high weekly volatility at 6.70%. Key resistance is identified at $5.22, with support at $5.15. The consensus earnings estimate for Q3 2025 is -0.17. The analysis concludes with an expectation for Nuvation Bio to open higher by approximately $0.0467, trading at $5.22 on November 4th, suggesting a buying opportunity in the short-term.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Analyst snapshot

StockInvest.us

Platform-wide history, separate from this source evaluation.

Reliability
53.4
Tracked signals
1779
Historical success
42.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail